ABSTRACT
Background: Bone metastasis with advance cancer stage forms approximately 85% of all cases. Breast cancer patients frequently suffer from
bone pain, functional impairment due to bone metastasis which impacts negatively on their quality of life. Subjects and Methods: A
retrospective study of breast cancer patients who have bone metastasis at
diagnosis or developing bone metastasis during 5 years from breast cancer
diagnosis (2011-2016) and who received zometa 4 mg
monthly in radiotherapy department was included and conducted in 2017. We reviewed 107 female with breast cancer
diagnosed by bone scan and/or PET scan as cases of bone metastasis enrolled.
Questionnaire was designed to document all variables besides, demographic data
which contain (age, histopathology reading invasive ductal carcinoma, invasive
lobular carcinoma or others, ER
status, PR status, Her2neu status and lymph
node status & stage, Onset of metastasis, Menopausal Status & finally No.
of metastasis site). Results: We noticed
that the highest percentage of patients diagnosed as bone metastasis were 45
years and more, and 86% of them were invasive ductal carcinoma; regarding
hormonal status we noticed that ER, PR status was positive in 90.7% and 82.2%
of cases respectively, Her2neu receptors were amplified in 26.2% of them,
positive lymph nodes were seen positive in 80.4% of cases and 31.8% of them were shown (N3) stage; we noticed that the only risk factor of bone metastasis is PR+ significantly
associated with lesions multiplicity (0.049). There is no significant
association between ER, PR, Her2neu, lymph nodes and menopausal status and
onset of bone metastasis, also age, ER, Her2neu, lymph nodes and menopausal
status are not associated significantly with No. of metastatic lesions. Conclusion:
PR+ is significantly associated with lesions multiplicity (0.049), which
is considered as a risk factor of bone metastasis in our study.